柳氮磺吡啶联合甲氨蝶呤治疗强直性脊柱炎的效果研究OA
Study of Efficacy about Sulfasalazine Combined with Methotrexate in the Treatment of Ankylosing Spondylitis
目的:探究对强制性脊柱炎患者应用柳氮磺吡啶联合甲氨蝶呤治疗的效果.方法:选取我院2020年2月—2023年2月收治的 86例强直性脊柱炎患者为研究对象,采用电脑抽号法将其分为研究组和对照组,每组 43例,2组患者均给予甲氨蝶呤药物治疗,研究组患者在以上基础上给予柳氮磺吡啶治疗,对比 2组患者治疗效果.结果:治疗前,2组的血清骨保护素、细胞核因子κB受体活化因子配体、25-(OH)D3、维生素D受体及骨特异性碱性磷酸酶水平比较,组间差异无统计学意义(P>0.05);治疗后,2组的血清骨保护素、细胞核因子κB受体活化因子配体水平均较治疗前降低,25-(OH)D3、维生素D受体及骨特异性碱性磷酸酶水平均较治疗前升高,且研究组血清骨保护素、细胞核因子κB受体活化因子配体水平均低于对照组,25-(OH)D3、维生素D受体及骨特异性碱性磷酸酶水平均高于对照组,差异有统计学意义(P<0.05).研究组的治疗有效率为 97.67%,高于对照组的83.72%,差异有统计学意义(P<0.05);治疗前,2组的MMP-9、hs-CRP、TNF-α、IL-6水平比较,组间差异无统计学意义(P>0.05);治疗后,2组的MMP-9 水平均较治疗前升高,hs-CRP、TNF-α、IL-6水平均较治疗前降低,且研究组MMP-9水平高于对照组,hs-CRP、TNF-α、IL-6水平均低于对照组,差异有统计学意义(P<0.05);研究组的不良反应发生率为2.32%,低于对照组的18.60%,差异有统计学意义(P<0.05).结论:对强制性脊柱炎患者进行治疗的过程中,应用甲氨蝶呤治疗的同时再为患者提供柳氮磺吡啶治疗,这种方式对于患者的应用效果十分显著.
Objective:To explore the effect of sulfasalazine combined with methotrexate in patients with coercive spondylitis.Methods:86 patients with ankylosing spondylitis admitted to our hospital from February 2020 to February 2023 were selected as the research objects.The patients were divided into a study group and a control group by computer sampling method,with 43 cases in each group.Patients in both groups were treated with methotrexate,and patients in the study group were treated with salazopyridine on the basis of the above,and the therapeutic effect of the two groups was compared.Results:Before treatment,there were no significant differences in serum osteoprotegerin,receptor activator of nuclear factor-κb ligand,25-(OH)D3,vitamin D receptor,and bone-specific alkaline phosphatase levels between the two groups(P>0.05).After treatment,the levels of serum osteoprotegerin and receptor activator of nuclear factor-κb ligand in the two groups were lower than those before treatment,and the levels of 25-(OH)D3,vitamin D receptor and bone specific alkaline phosphatase were higher than those before treatment,and the levels of serum osteoprotegerin and receptor activator of nuclear factor-κb ligand in the study group were lower than those in the control group.The levels of 25-(OH)D3,vitamin D receptor and bone specific alkaline phosphatase in the experimental group were higher than those in the control group,and the differences were statistically significant(P<0.05).The effective rate of the study group was 97.67%,which was higher than 83.72%of the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of MMP-9,hs-CRP,TNF-α and IL-6 between the two groups(P>0.05).After treatment,the levels of MMP-9 in the two groups were higher than those before treatment,and the levels of hs-CRP,TNF-α and IL-6 were lower than those before treatment,and the level of MMP-9 in the study group was higher than that in the control group,and the levels of hs-CRP,TNF-α and IL-6 were lower than those in the control group and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 2.32%,which was lower than 18.60%in the control group,and the difference was statistically significant(P<0.05).Conclusion:In the treatment of patients with ankylosing spondylitis,the application of methotrexate and sulfasalazine treatment is very effective for patients.
李丹;李冬民
西安交通大学基础医学院,陕西 西安 710049||西安市长安区医院西安交通大学基础医学院,陕西 西安 710049
临床医学
强直性脊柱炎柳氮磺吡啶甲氨蝶呤骨特异性碱性磷酸酶
Ankylosing spondylitisSulfasalazineMethotrexateBone-specific alkaline phosphatase
《中国伤残医学》 2024 (004)
56-59,71 / 5
评论